{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:48:41Z","timestamp":1792684121064,"version":"4.5.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007156","name":"Innovation and Technology Commission - Hong Kong","doi-asserted-by":"publisher","award":["AIR@InnoHK"],"award-info":[{"award-number":["AIR@InnoHK"]}],"id":[{"id":"10.13039\/501100007156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007156","name":"Innovation and Technology Commission - Hong Kong","doi-asserted-by":"publisher","award":["AIR@InnoHK"],"award-info":[{"award-number":["AIR@InnoHK"]}],"id":[{"id":"10.13039\/501100007156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clozapine is widely regarded as a highly efficacious psychotropic drug that is largely underused worldwide. Recent disproportionality analyses and nationwide case-control studies suggested a potential association between clozapine use and hematological malignancy (HM). Nevertheless, the absolute rate difference is not well-established due to the absence of analytic cohort studies. The clinical significance of such a potential risk remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We extracted data from a territory-wide public healthcare database from January 2001 to August 2022 in Hong Kong to conduct a retrospective cohort study of anonymized patients aged 18\n                      <jats:sup>+<\/jats:sup>\n                      years with a diagnosis of schizophrenia who used clozapine or olanzapine (drug comparator with highly similar chemical structure and pharmacological mechanisms) for 90\n                      <jats:sup>+<\/jats:sup>\n                      days, with at least 2 prior other antipsychotic use records within both groups. Weighted by inverse probability of treatment (IPTW) based on propensity scores, Poisson regression was used to estimate the incidence rate ratio (IRR) of HM between clozapine and olanzapine users. The absolute rate difference was also estimated. In total, 9,965 patients with a median follow-up period of 6.99 years (25th to 75th percentile: 4.45 to 10.32 years) were included, among which 834 were clozapine users. After IPTW, the demographic and clinical characteristics of clozapine users were comparable to those of olanzapine users. Clozapine users had a significant weighted IRR of 2.22 (95% confidence interval (CI) [1.52, 3.34];\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) for HM compared to olanzapine users. The absolute rate difference was estimated at 57.40 (95% CI [33.24, 81.55]) per 100,000 person-years. Findings were consistent across subgroups by age and sex. Sensitivity analyses all supported the robustness of the results and showed good specificity to HM but no other cancers. The main limitation of this observational study is the potential residual confounding effects that could have arisen from the lack of randomization in clozapine or olanzapine use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Absolute rate difference in HM incidence associated with clozapine is small despite a 2-fold elevated rate. Given the rarity of HM and existing blood monitoring requirements, more restrictive indication for clozapine or special warnings may not be necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004457","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T13:26:28Z","timestamp":1733405188000},"page":"e1004457","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2577-6882","authenticated-orcid":true,"given":"Yuqi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9349-6599","authenticated-orcid":true,"given":"Le","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2641-656X","authenticated-orcid":true,"given":"Lingyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2018-6072","authenticated-orcid":true,"given":"Cuiling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Yui Ki","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-1575","authenticated-orcid":true,"given":"Franco Wing Tak","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Kwun Nam","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3867-6447","authenticated-orcid":true,"given":"Amy Pui Pui","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2551-5230","authenticated-orcid":true,"given":"Heidi Ka Ying","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4138-8219","authenticated-orcid":true,"given":"Krystal Chi Kei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3581-8895","authenticated-orcid":true,"given":"Wing Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-4055","authenticated-orcid":true,"given":"William Chi Wai","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":true,"given":"Esther Wai Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":true,"given":"Ian Chi Kei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9191-2341","authenticated-orcid":true,"given":"Yi","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9121-1959","authenticated-orcid":true,"given":"Francisco Tsz Tsun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"issue":"1","key":"pmed.1004457.ref001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"H Taipale","year":"2020","journal-title":"World Psychiatry"},{"issue":"2","key":"pmed.1004457.ref002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1\u201312.5 Years","volume":"45","author":"JM Vermeulen","year":"2019","journal-title":"Schizophr Bull"},{"issue":"1","key":"pmed.1004457.ref003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S2215-0366(23)00406-6","article-title":"Clozapine: past, present, and future","volume":"11","author":"Lancet Psychiatry","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"pmed.1004457.ref004","doi-asserted-by":"crossref","first-page":"101906","DOI":"10.1016\/j.ajp.2019.101906","article-title":"Haematological side effects associated with clozapine: A retrospective study from India","volume":"48","author":"S Grover","year":"2020","journal-title":"Asian J Psychiatr"},{"issue":"9","key":"pmed.1004457.ref005","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291720000161","article-title":"Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase(\u00ae)","volume":"51","author":"B Chr\u00e9tien","year":"2021","journal-title":"Psychol Med"},{"issue":"8","key":"pmed.1004457.ref006","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1017\/S0033291720001233","article-title":"The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase","volume":"51","author":"J de Leon","year":"2021","journal-title":"Psychol Med"},{"issue":"5","key":"pmed.1004457.ref007","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2215-0366(22)00044-X","article-title":"Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland","volume":"9","author":"J Tiihonen","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"pmed.1004457.ref008","doi-asserted-by":"crossref","first-page":"23m15149","DOI":"10.4088\/JCP.23m15149","article-title":"Association Between Clozapine Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia","volume":"85","author":"DR Brainerd","year":"2024","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"pmed.1004457.ref009","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"J Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"pmed.1004457.ref010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40267-023-00982-6","article-title":"Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management","volume":"39","author":"C Fenton","year":"2023","journal-title":"Drugs Ther Perspect"},{"key":"pmed.1004457.ref011","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1017\/S2045796023000732","article-title":"Characterization of antipsychotic utilization before clozapine initiation for individuals with schizophrenia: an innovative visualization of trajectories using French National Health Insurance data","volume":"32","author":"EJ Laforgue","year":"2023","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"2","key":"pmed.1004457.ref012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1017\/S1092852912000806","article-title":"Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses","volume":"18","author":"JS Souza","year":"2013","journal-title":"CNS Spectr"},{"key":"pmed.1004457.ref013","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231168788","article-title":"High-dose olanzapine in treatment-resistant schizophrenia: a systematic review","volume":"13","author":"L Gannon","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"pmed.1004457.ref014","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M21-3700","article-title":"Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case-Control Study","volume":"175","author":"FTT Lai","year":"2022","journal-title":"Ann Intern Med"},{"issue":"6","key":"pmed.1004457.ref015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2215-0366(23)00111-6","article-title":"Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study","volume":"10","author":"C Huang","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"pmed.1004457.ref016","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2017.1363","article-title":"Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation","volume":"317","author":"WC Lau","year":"2017","journal-title":"JAMA"},{"key":"pmed.1004457.ref017","first-page":"j2350","article-title":"Prenatal antidepressant use and risk of attention-deficit\/hyperactivity disorder in offspring: population based cohort study","volume":"357","author":"KKC Man","year":"2017","journal-title":"BMJ"},{"key":"pmed.1004457.ref018","doi-asserted-by":"crossref","first-page":"h6926","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: population based study","volume":"352","author":"AY Wong","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"pmed.1004457.ref019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine","volume":"37","author":"JT Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"pmed.1004457.ref020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.semcancer.2019.06.005","article-title":"Autoimmune diseases and hematological malignancies: Exploring the underlying mechanisms from epidemiological evidence","volume":"64","author":"K Hemminki","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"pmed.1004457.ref021","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3018(20)30118-1","article-title":"Epidemiology of haematological malignancies in people living with HIV","volume":"7","author":"SM Kimani","year":"2020","journal-title":"Lancet HIV"},{"issue":"2","key":"pmed.1004457.ref022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"N Myles","year":"2018","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"pmed.1004457.ref023","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0004867419833166","article-title":"A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia","volume":"53","author":"N Myles","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"pmed.1004457.ref024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13651500903402450","article-title":"Incidence and risk for neutropenia\/agranulocytosis among clozapine users: A retrospective cohort study","volume":"14","author":"C Ratanajamit","year":"2010","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"4","key":"pmed.1004457.ref025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/JCP.0000000000001699","article-title":"Hematological and Other Cancers in People Using Clozapine: Analysis of Australian Spontaneous Reports Between 1995 and 2020","volume":"43","author":"JL Dawson","year":"2023","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"pmed.1004457.ref026","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia","volume":"36","author":"CU Correll","year":"2022","journal-title":"CNS Drugs"},{"issue":"5","key":"pmed.1004457.ref027","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/EDE.0000000000001521","article-title":"Selection of Comparator Group in Observational Drug Safety Studies: Alternatives to the Active Comparator New User Design","volume":"33","author":"V Wintzell","year":"2022","journal-title":"Epidemiology"},{"issue":"1","key":"pmed.1004457.ref028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JCP.0000000000001329","article-title":"Clozapine Response in Schizophrenia and Hematological Changes","volume":"41","author":"G Blackman","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"pmed.1004457.ref029","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hup.1181","article-title":"Haematological toxicity of clozapine and some other drugs used in psychiatry.","volume":"26","author":"PMM Nooijen","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"pmed.1004457.ref030","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case\u2013control study in Finland","author":"JM Rubio","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"pmed.1004457.ref031","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1159\/000369751","article-title":"Clozapine Induces Autophagic Cell Death in Non-Small Cell Lung Cancer Cells","volume":"35","author":"Y-C Yin","year":"2015","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"pmed.1004457.ref032","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"D De Berardis","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"pmed.1004457.ref033","doi-asserted-by":"crossref","first-page":"609240","DOI":"10.3389\/fendo.2021.609240","article-title":"A focused review of the metabolic side-effects of clozapine.","volume":"12","author":"JW Yuen","year":"2021","journal-title":"Front Endocrinol"},{"issue":"3","key":"pmed.1004457.ref034","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/wps.20446","article-title":"Improving outcomes of first-episode psychosis: an overview","volume":"16","author":"P Fusar-Poli","year":"2017","journal-title":"World Psychiatry"},{"issue":"1","key":"pmed.1004457.ref035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review","volume":"11","author":"E Wagner","year":"2021","journal-title":"Transl Psychiatry"},{"key":"pmed.1004457.ref036","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231168788","article-title":"High-dose olanzapine in treatment-resistant schizophrenia: a systematic review","volume":"13","author":"L Gannon","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"issue":"2","key":"pmed.1004457.ref037","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40263-023-01054-z","article-title":"Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review","volume":"38","author":"S Smessaert","year":"2024","journal-title":"CNS Drugs"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T13:26:43Z","timestamp":1733405203000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004457"}},"subtitle":[],"editor":[{"given":"Seena","family":"Fazel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004457","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.07.24311592","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}